NOVARTIS AG holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 11,818,102 | $1,317,482,011 | 0.75% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2025 |
| June 30, 2025 | 10,647,629 | $1,288,469,585 | 0.72% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2025 |
| Sept. 30, 2025 | 10,585,145 | $1,357,438,995 | 0.73% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 13, 2025 |
| Dec. 31, 2025 | 9,014,641 | $1,242,848,555 | 0.67% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 13, 2026 |
| March 31, 2026 | 6,967,383 | $1,064,267,753 | 0.58% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2026 |
| June 30, 2026 | 759,373 | $119,008,937 | 0.06% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.